share_log

維亞生物：截至二零二四年二月二十九日止月份股份發行人的證券變動月報表

VIVA BIOTECH: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024

香港交易所 ·  Mar 1 05:18
Summary by Moomoo AI
维亚生物科技控股集团於2024年2月29日提交了最新的證券變動月報表給香港交易及結算所有限公司。報告顯示，截至2024年2月底，公司的法定/註冊股本結存維持在4,000,000,000股，每股面值0.000025美元，總股本金額為100,000美元，本月內無增減變動。此外，公司的股份期權計劃包括首次公開發售前股份獎勵計劃和首次公開發售後購股權計劃，其中首次公開發售前股份獎勵計劃本月底結存的股份期權數為3,665,141股，而首次公開發售後購股權計劃則有26,800,000股已授出的股份期權。報告中未提及其他類型的證券變動。毛晨，執行董事，於2024年3月1日呈交了此份報告。
维亚生物科技控股集团於2024年2月29日提交了最新的證券變動月報表給香港交易及結算所有限公司。報告顯示，截至2024年2月底，公司的法定/註冊股本結存維持在4,000,000,000股，每股面值0.000025美元，總股本金額為100,000美元，本月內無增減變動。此外，公司的股份期權計劃包括首次公開發售前股份獎勵計劃和首次公開發售後購股權計劃，其中首次公開發售前股份獎勵計劃本月底結存的股份期權數為3,665,141股，而首次公開發售後購股權計劃則有26,800,000股已授出的股份期權。報告中未提及其他類型的證券變動。毛晨，執行董事，於2024年3月1日呈交了此份報告。
VIA BIOTECHNOLOGY HOLDINGS GROUP SUBMITTED ITS LATEST MONTHLY STATEMENT OF SECURITIES CHANGES TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 29 FEBRUARY 2024. As of the end of February 2024, the Company's regulated/registered share capital remained at 4,000,000,000 shares with a face value of $0.000025 per share and a total share capital of $100,000, unchanged during the month, according to the report. In addition, the Company's share option plans include the Initial Public Offering Share Award Scheme and the Initial Public Post-IPO Share Option Scheme, where the number of stock options outstanding at the end of the month is 3,665,141 shares under the Initial Public Offering pre-IPO share bonus scheme and 26,800,000 shares granted under the IPO Stock options. Changes in other types of securities are not mentioned in the report. Mao Chen, Executive Director, submitted this report on March 1, 2024.
VIA BIOTECHNOLOGY HOLDINGS GROUP SUBMITTED ITS LATEST MONTHLY STATEMENT OF SECURITIES CHANGES TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 29 FEBRUARY 2024. As of the end of February 2024, the Company's regulated/registered share capital remained at 4,000,000,000 shares with a face value of $0.000025 per share and a total share capital of $100,000, unchanged during the month, according to the report. In addition, the Company's share option plans include the Initial Public Offering Share Award Scheme and the Initial Public Post-IPO Share Option Scheme, where the number of stock options outstanding at the end of the month is 3,665,141 shares under the Initial Public Offering pre-IPO share bonus scheme and 26,800,000 shares granted under the IPO Stock options. Changes in other types of securities are not mentioned in the report. Mao Chen, Executive Director, submitted this report on March 1, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more